Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
hereditary angioedema market 2027

SALE

Hereditary Angioedema - Market Insight, Epidemiology and Market Forecast - 2027

Published Date : 2018

Pages : 100

Region : United States, Japan, EU4 & UK

SALE

Summary
TOC Table of Content
LOT
- Sample Request

hereditary angioedema market 2027

DelveInsight's "Hereditary Angioedema - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Hereditary Angioedema epidemiology and market outlook for the 7MM.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Hereditary Angioedema Understanding and Treatment Algorithm

The market report provides the overview of the Hereditary Angioedema by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Hereditary Angioedema Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Hereditary Angioedema in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Hereditary Angioedema Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Hereditary Angioedema Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Hereditary Angioedema market.

Hereditary Angioedema Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Hereditary Angioedema Report Insights

• Patient Population in Hereditary Angioedema

• Therapeutic Approaches in Hereditary Angioedema

• Hereditary Angioedema Pipeline Analysis

• Hereditary Angioedema Market Size and Trends

• Hereditary Angioedema Market Opportunities

• Impact of upcoming Therapies in Hereditary Angioedema

Hereditary Angioedema Report Key Strengths

• 10 Year Forecast

• 7MM Coverage

• Epidemiology Segmentation

• Drugs Uptake

• Highly Analyzed Market

• Key Cross Competition

Hereditary Angioedema Report Assessment

• Current Treatment Practices in Hereditary Angioedema

• Unmet Needs in Hereditary Angioedema

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• The report will help to develop Business Strategies by understanding the trends shaping and driving the Hereditary Angioedema market

• Organize sales and marketing efforts by identifying the best opportunities for Hereditary Angioedema market

• To understand the future market competition in the Hereditary Angioedema market.

1. Report Introduction

2. Hereditary Angioedema Market Overview at a Glance

2.1. Market Share Distribution of Hereditary Angioedema in 2017

2.2. Market Share Distribution of Hereditary Angioedema in 2027

3. Disease Background and Overview: Hereditary Angioedema

3.1. Introduction

3.2. Symptoms

3.3. Etiology

3.4. Risk Factors

3.5. Pathophysiology

3.6. Diagnosis

3.7. Treatment

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Total Prevalent/ Incident Patient Population of Hereditary Angioedema in 7MM

4.3. Total Prevalent Patient Population of Hereditary Angioedema in 7MM - By Countries

5. Epidemiology of Hereditary Angioedema by Countries

5.1. United States

5.1.1. Assumptions and Rationale

5.1.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.1.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.1.4. Sex- Specific Cases of the Hereditary Angioedema *

5.1.5. Diagnosed Cases of the Hereditary Angioedema

5.1.6. Treatable Cases of the Hereditary Angioedema

5.2. EU5

5.3. Assumptions and Rationale

5.4. Germany

5.4.1. Assumptions and Rationale

5.4.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.4.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.4.4. Sex- Specific Cases of the Hereditary Angioedema *

5.4.5. Diagnosed Cases of the Hereditary Angioedema

5.4.6. Treatable Cases of the Hereditary Angioedema

5.5. France

5.5.1. Assumptions and Rationale

5.5.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.5.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.5.4. Sex- Specific Cases of the Hereditary Angioedema *

5.5.5. Diagnosed Cases of the Hereditary Angioedema

5.5.6. Treatable Cases of the Hereditary Angioedema

5.6. Italy

5.6.1. Assumptions and Rationale

5.6.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.6.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.6.4. Sex- Specific Cases of the Hereditary Angioedema *

5.6.5. Diagnosed Cases of the Hereditary Angioedema

5.6.6. Treatable Cases of the Hereditary Angioedema

5.7. Spain

5.7.1. Assumptions and Rationale

5.7.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.7.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.7.4. Sex- Specific Cases of the Hereditary Angioedema *

5.7.5. Diagnosed Cases of the Hereditary Angioedema

5.7.6. Treatable Cases of the Hereditary Angioedema

5.8. United Kingdom

5.8.1. Assumptions and Rationale

5.8.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.8.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.8.4. Sex- Specific Cases of the Hereditary Angioedema *

5.8.5. Diagnosed Cases of the Hereditary Angioedema

5.8.6. Treatable Cases of the Hereditary Angioedema

5.9. Japan

5.9.1. Assumptions and Rationale

5.9.2. Prevalent/Incident Cases of the Hereditary Angioedema

5.9.3. Sub-Type Specific cases of the Hereditary Angioedema *

5.9.4. Sex- Specific Cases of the Hereditary Angioedema *

5.9.5. Diagnosed Cases of the Hereditary Angioedema

5.9.6. Treatable Cases of the Hereditary Angioedema

6. Current Treatment & Medical practices

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. Unmet Needs of the Hereditary Angioedema

8. Marketed Therapies

8.1. Drug A: Company 1

8.1.1. Drug Description

8.1.2. Mechanism of Action

8.1.3. Regulatory Milestones

8.1.4. Advantages & Disadvantages

8.1.5. Product Profile

8.2. Drug B: Company 2

8.2.1. Drug Description

8.2.2. Mechanism of Action

8.2.3. Regulatory Milestones

8.2.4. Advantages & Disadvantages

8.2.5. Product Profile

9. Pipeline Therapies - At a glance

10. Key Cross Competition

11. Emerging Therapies for Hereditary Angioedema

11.1. Drug C: Company 3

11.1.1. Drug Description

11.1.2. Clinical Trials Details

11.1.3. Safety and Efficacy Profile

11.1.4. Advantages & Disadvantages

11.1.5. Pipeline Development Activities

11.1.6. Product Profile

11.2. Drug D: Company 4

11.2.1. Drug Description

11.2.2. Clinical Trials Details

11.2.3. Safety and Efficacy Profile

11.2.4. Advantages & Disadvantages

11.2.5. Pipeline Development Activities

11.2.6. Product Profile

12. Hereditary Angioedema : 7MM Market Analysis

12.1. 7MM Market Size of Hereditary Angioedema

12.2. 7MM Percentage Share of drugs marketed for Hereditary Angioedema

12.3. 7MM Market Sales of Hereditary Angioedema by Products

13. Hereditary Angioedema : Country-Wise Market Analysis

13.1. United States

13.1.1. Market Size of Hereditary Angioedema in United States

13.1.2. Percentage Share of drugs marketed for Hereditary Angioedema in United States

13.1.3. Market Sales of Hereditary Angioedema by Products in United States

13.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2. EU-5

13.2.1. Germany

13.2.1.1. Market Size of Hereditary Angioedema in Germany

13.2.1.2. Percentage Share of drugs marketed for Hereditary Angioedema in Germany

13.2.1.3. Market Sales of Hereditary Angioedema by Products in Germany

13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.2. France

13.2.2.1. Market Size of Hereditary Angioedema in France

13.2.2.2. Percentage Share of drugs marketed for Hereditary Angioedema in France

13.2.2.3. Market Sales of Hereditary Angioedema by Products in France

13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.3. Italy

13.2.3.1. Market Size of Hereditary Angioedema in Italy

13.2.3.2. Percentage Share of drugs marketed for Hereditary Angioedema in Italy

13.2.3.3. Market Sales of Hereditary Angioedema by Products in Italy

13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.4. Spain

13.2.4.1. Market Size of Hereditary Angioedema in Spain

13.2.4.2. Percentage Share of drugs marketed for Hereditary Angioedema in Spain

13.2.4.3. Market Sales of Hereditary Angioedema by Products in Spain

13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market

13.2.5. United Kingdom

13.2.5.1. Market Size of Hereditary Angioedema in United Kingdom

13.2.5.2. Percentage Share of drugs marketed for Hereditary Angioedema in United Kingdom

13.2.5.3. Market Sales of Hereditary Angioedema by Products in United Kingdom

13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market

13.3. Japan

13.3.1. Market Size of Hereditary Angioedema in Japan

13.3.2. Percentage Share of drugs marketed for Hereditary Angioedema in Japan

13.3.3. Market Sales of Hereditary Angioedema by Products in Japan

13.3.4. Analysis of Upcoming Therapies and their Impact on the Market

14. Market Drivers

15. Market Barriers

16. Appendix

17. Report Methodology

17.1. Sources

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

*Indication Specific

List of Tables:

Table 1: Total Prevalent/Incident Cases of the Hereditary Angioedema in 7MM

Table 2: Total Prevalent/Incident Cases of the Hereditary Angioedema in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Hereditary Angioedema in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Hereditary Angioedema in United States (2016-2027)

Table 5: Sex- Specific Cases of the Hereditary Angioedema in United States (2016-2027)

Table 6: Diagnosed Cases of the Hereditary Angioedema in United States (2016-2027)

Table 7: Treatable Cases of the Hereditary Angioedema in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Hereditary Angioedema in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Hereditary Angioedema in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Hereditary Angioedema in Germany (2016-2027)

Table 11: Diagnosed Cases of the Hereditary Angioedema in Germany (2016-2027)

Table 12: Treatable Cases of the Hereditary Angioedema in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Hereditary Angioedema in France (2016-2027)

Table 14: Sub-Type Specific cases of the Hereditary Angioedema in France (2016-2027)

Table 15: Sex- Specific Cases of the Hereditary Angioedema in France (2016-2027)

Table 16: Diagnosed Cases of the Hereditary Angioedema in France (2016-2027)

Table 17: Treatable Cases of the Hereditary Angioedema in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Hereditary Angioedema in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Hereditary Angioedema in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Hereditary Angioedema in Italy (2016-2027)

Table 21: Diagnosed Cases of the Hereditary Angioedema in Italy (2016-2027)

Table 22: Treatable Cases of the Hereditary Angioedema in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Hereditary Angioedema in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Hereditary Angioedema in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Hereditary Angioedema in Spain (2016-2027)

Table 26: Diagnosed Cases of the Hereditary Angioedema in Spain (2016-2027)

Table 27: Treatable Cases of the Hereditary Angioedema in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Hereditary Angioedema in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Hereditary Angioedema in UK (2016-2027)

Table 30: Sex- Specific Cases of the Hereditary Angioedema in UK (2016-2027)

Table 31: Diagnosed Cases of the Hereditary Angioedema in UK (2016-2027)

Table 32: Treatable Cases of the Hereditary Angioedema in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Hereditary Angioedema in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Hereditary Angioedema in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Hereditary Angioedema in Japan (2016-2027)

Table 36: Diagnosed Cases of the Hereditary Angioedema in Japan (2016-2027)

Table 37: Treatable Cases of the Hereditary Angioedema in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 42:7MM- Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 45: United States-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 48: Germany-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 51: France-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 54: Italy-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 57: Spain-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 60:UK-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Table 63: Japan-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

List of Figures:

Figure 1: Total Prevalent/Incident Cases of the Hereditary Angioedema in 7MM

Figure 2: Total Prevalent/Incident Cases of the Hereditary Angioedema in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Hereditary Angioedema in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Hereditary Angioedema in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Hereditary Angioedema in United States (2016-2027)

Figure 6: Diagnosed Cases of the Hereditary Angioedema in United States (2016-2027)

Figure 7: Treatable Cases of the Hereditary Angioedema in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Hereditary Angioedema in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Hereditary Angioedema in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Hereditary Angioedema in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Hereditary Angioedema in Germany (2016-2027)

Figure 12: Treatable Cases of the Hereditary Angioedema in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Hereditary Angioedema in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Hereditary Angioedema in France (2016-2027)

Figure 15: Sex- Specific Cases of the Hereditary Angioedema in France (2016-2027)

Figure 16: Diagnosed Cases of the Hereditary Angioedema in France (2016-2027)

Figure 17: Treatable Cases of the Hereditary Angioedema in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Hereditary Angioedema in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Hereditary Angioedema in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Hereditary Angioedema in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Hereditary Angioedema in Italy (2016-2027)

Figure 22: Treatable Cases of the Hereditary Angioedema in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Hereditary Angioedema in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Hereditary Angioedema in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Hereditary Angioedema in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Hereditary Angioedema in Spain (2016-2027)

Figure 27: Treatable Cases of the Hereditary Angioedema in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Hereditary Angioedema in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Hereditary Angioedema in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Hereditary Angioedema in UK (2016-2027)

Figure 31: Diagnosed Cases of the Hereditary Angioedema in UK (2016-2027)

Figure 32: Treatable Cases of the Hereditary Angioedema in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Hereditary Angioedema in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Hereditary Angioedema in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Hereditary Angioedema in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Hereditary Angioedema in Japan (2016-2027)

Figure 37: Treatable Cases of the Hereditary Angioedema in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41:7MM- Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 42:7MM- Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 43:7MM- Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 45: United States-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 48: Germany-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 51: France-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 54: Italy-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 57: Spain-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 60:UK-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Hereditary Angioedema in USD MM (2016-2027)

Figure 63: Japan-Market Share Hereditary Angioedema by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Hereditary Angioedema by Therapies in USD MM (2016-2027)

Tags:

License Type

Offer